[go: up one dir, main page]

PL3986890T3 - Pochodne benzizoksazolosulfonamidu - Google Patents

Pochodne benzizoksazolosulfonamidu

Info

Publication number
PL3986890T3
PL3986890T3 PL20743773.2T PL20743773T PL3986890T3 PL 3986890 T3 PL3986890 T3 PL 3986890T3 PL 20743773 T PL20743773 T PL 20743773T PL 3986890 T3 PL3986890 T3 PL 3986890T3
Authority
PL
Poland
Prior art keywords
sulfonamide derivatives
benzisoxazole
benzisoxazole sulfonamide
derivatives
sulfonamide
Prior art date
Application number
PL20743773.2T
Other languages
English (en)
Inventor
Ylva Elisabet Bergman BOZIKIS
Oleg Brodsky
Michelle Ang CAMERINO
Samantha Elizabeth GREASLEY
Robert Louis Hoffman
Robert Arnold Kumpf
Pei-Pei Kung
Paul Francis Richardson
Paul Anthony Stupple
Scott Channing Sutton
Original Assignee
Pfizer Inc.
Ctxt Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc., Ctxt Pty Ltd filed Critical Pfizer Inc.
Publication of PL3986890T3 publication Critical patent/PL3986890T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PL20743773.2T 2019-06-18 2020-06-16 Pochodne benzizoksazolosulfonamidu PL3986890T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962863199P 2019-06-18 2019-06-18
US201962953223P 2019-12-24 2019-12-24
US202063025278P 2020-05-15 2020-05-15
PCT/IB2020/055589 WO2020254946A1 (en) 2019-06-18 2020-06-16 Benzisoxazole sulfonamide derivatives

Publications (1)

Publication Number Publication Date
PL3986890T3 true PL3986890T3 (pl) 2024-03-11

Family

ID=71738189

Family Applications (2)

Application Number Title Priority Date Filing Date
PL23203023.9T PL4299135T3 (pl) 2019-06-18 2020-06-16 Pochodne benzizoksazolosulfonamidu
PL20743773.2T PL3986890T3 (pl) 2019-06-18 2020-06-16 Pochodne benzizoksazolosulfonamidu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL23203023.9T PL4299135T3 (pl) 2019-06-18 2020-06-16 Pochodne benzizoksazolosulfonamidu

Country Status (33)

Country Link
US (2) US11492346B2 (pl)
EP (2) EP3986890B9 (pl)
JP (2) JP7352662B2 (pl)
KR (1) KR102823056B1 (pl)
CN (1) CN114364672B (pl)
AU (2) AU2020296361A1 (pl)
BR (1) BR112021025528A2 (pl)
CA (1) CA3143666C (pl)
CL (1) CL2021003372A1 (pl)
CO (1) CO2021017504A2 (pl)
CR (1) CR20210627A (pl)
DK (2) DK4299135T3 (pl)
EC (1) ECSP21091615A (pl)
ES (2) ES2969616T3 (pl)
FI (2) FI3986890T3 (pl)
HR (2) HRP20251225T1 (pl)
HU (1) HUE064683T2 (pl)
IL (1) IL288802B2 (pl)
LT (2) LT3986890T (pl)
MA (1) MA67365B1 (pl)
MD (2) MD3986890T3 (pl)
MX (1) MX2021016085A (pl)
MY (1) MY210207A (pl)
PE (1) PE20220808A1 (pl)
PH (1) PH12021553107A1 (pl)
PL (2) PL4299135T3 (pl)
PT (2) PT3986890T (pl)
RS (2) RS67276B1 (pl)
SI (1) SI3986890T1 (pl)
TW (1) TWI787620B (pl)
UA (1) UA129891C2 (pl)
UY (1) UY38752A (pl)
WO (1) WO2020254946A1 (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201810092D0 (en) * 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
KR20220034739A (ko) 2019-05-31 2022-03-18 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
FI3986890T3 (fi) 2019-06-18 2024-01-15 Pfizer Bentsisoksatsolisulfonamidijohdannaisia
AU2020295006B2 (en) * 2019-06-19 2023-11-09 Ctxt Pty Ltd Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives
US20220024919A1 (en) * 2020-07-15 2022-01-27 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
BR112023000687A2 (pt) * 2020-07-15 2023-02-07 Pfizer Métodos e combinações de inibidores de kat6 para o tratamento de câncer
WO2022187688A1 (en) * 2021-03-05 2022-09-09 Umbra Therapeutics Inc. Covalent kras-binding compounds for therapeutic purposes
WO2022187693A1 (en) * 2021-03-05 2022-09-09 Umbra Therapeutics Inc. Covalent cdk2-binding compounds for therapeutic purposes
MX2023013683A (es) * 2021-05-21 2024-02-23 Aurigene Oncology Ltd Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a).
WO2023280182A1 (zh) * 2021-07-05 2023-01-12 杭州英创医药科技有限公司 作为kat6抑制剂的化合物
KR20240046530A (ko) 2021-08-10 2024-04-09 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 설폰아미드 유도체, 이의 제조 방법 및 이의 의학적 용도
AU2022390319A1 (en) * 2021-11-16 2024-05-30 Insilico Medicine Ip Limited Lysine acetyltransferase 6a (kat6a) inhibitors and uses thereof
EP4448109A1 (en) * 2021-12-13 2024-10-23 Aurigene Oncology Limited Fused benzoisoxazolyl compounds as kat6a inhibitors
CN116621859A (zh) * 2022-02-18 2023-08-22 山东轩竹医药科技有限公司 三并环类kat6抑制剂
CN119301096A (zh) 2022-03-28 2025-01-10 伊索斯泰里克斯公司 Myst家族赖氨酸乙酰转移酶的抑制剂
US20230416240A1 (en) * 2022-06-16 2023-12-28 Prelude Therapeutics Incorporated Kat6 targeting compounds
WO2024023703A1 (en) 2022-07-29 2024-02-01 Pfizer Inc. Dosing regimens comprising a kat6 inhibitor for the treatment of cancer
CN120476113A (zh) * 2022-12-20 2025-08-12 杭州中美华东制药有限公司 具有sting抑制作用的含肟化合物及其药物组合物和用途
AU2024217108A1 (en) 2023-02-10 2025-09-18 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Crystalline form of sulfonamide derivative and preparation method therefor
WO2024189598A2 (en) 2023-03-16 2024-09-19 Olema Pharmaceuticals, Inc. Acylsulfonamide kat6a inhibitors
KR20250157556A (ko) * 2023-03-27 2025-11-04 베이징 콘런스 파마슈티칼 컴퍼니 리미티드 설폰아미드 화합물, 이의 약학적 조성물과 응용
KR20250164842A (ko) 2023-03-30 2025-11-25 화이자 인코포레이티드 Kat6a 억제제에 의한 치료를 위한 예측 바이오마커로서의 kat6a 및 이의 치료 방법
AU2024259385A1 (en) * 2023-04-19 2025-12-04 Insilico Medicine Ip Limited Lysine acetyltransferase 6a (kat6a) inhibitor, combinations and uses thereof
WO2024222725A1 (en) * 2023-04-25 2024-10-31 Insilico Medicine Ip Limited Crystalline lysine acetyltransferase 6a (kat6a) inhibitor and uses thereof
TW202504580A (zh) * 2023-07-04 2025-02-01 大陸商上海齊魯製藥研究中心有限公司 Kat6抑制劑
WO2025036382A1 (zh) * 2023-08-14 2025-02-20 上海复宏汉霖生物医药有限公司 一种磺酰胺类化合物、其制备方法及用途
TW202530223A (zh) * 2023-09-27 2025-08-01 美商艾索司特瑞克斯公司 Myst抑制劑
WO2025098417A1 (zh) * 2023-11-08 2025-05-15 再和医药科技(苏州)有限公司 磺酰胺类化合物及其应用
WO2025141469A1 (en) 2023-12-26 2025-07-03 Pfizer Inc. Crystalline form of 2-methoxy-n-{4-methoxy-6-[(1h-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3064003A (en) 1962-11-13 Carboxylic acid derivatives of sub-
US2358031A (en) 1944-09-12 Substituted thiadiazoles
US2525321A (en) 1949-01-07 1950-10-10 American Cyanamid Co Hydroxybenzenesulfonamidoisoxazoles and preparation of same
GB689281A (en) 1950-02-18 1953-03-25 Lunbeck Corp Improvements in or relating to the production of sulphanilamido-thiadiazoles
DE1102745B (de) 1959-06-06 1961-03-23 Boehringer & Soehne Gmbh Verfahren zur Herstellung von 5-Sulfanilamidoisoxazolen
BE617370A (fr) 1961-05-09 1962-11-08 Ciba Geigy Procédé de préparation du 2,5-di-[benzoxazolyl-(2')]-thiofène
US3332942A (en) 1962-11-02 1967-07-25 White Lab Inc Substituted thiadiazoles
JPS498255B1 (pl) 1970-10-08 1974-02-25
US3951967A (en) 1972-03-20 1976-04-20 Merck & Co., Inc. 7-Mercapto(or thio)-benzothiadiazine products
US3960854A (en) 1972-03-20 1976-06-01 Merck & Co., Inc. 7-Mercapto(or thio)-benzothiadiazine products
DE2617809C2 (de) 1976-04-23 1984-09-20 Basf Ag, 6700 Ludwigshafen Verfahren zur Stabilisierung von Chromdioxid-Magnetpigmenten und seine Verwendung
JPS6042794B2 (ja) 1977-09-27 1985-09-25 三共株式会社 イソオキサゾリウム塩,およびその製造方法
US4251664A (en) 1978-05-24 1981-02-17 Henkel Corporation Sulfonamidothiadiazoles, metal complexes thereof, and solutions containing such compounds for use in extraction of metal values
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
JPS603685B2 (ja) 1980-04-15 1985-01-30 日本コロムビア株式会社 絵入りレコ−ド盤の製造方法
GB8427618D0 (en) 1984-11-01 1984-12-05 Shell Int Research Anticoccidial compositions
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
JPS63238006A (ja) 1987-03-26 1988-10-04 Shionogi & Co Ltd イモチ防除剤
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
NZ231534A (en) 1988-11-29 1992-02-25 Warner Lambert Co 3,5-di-t-butyl-4-hydroxyphenyl-triazoles, oxadiazoles and thiadiazoles; anti-inflammatory compositions
JPH03258771A (ja) 1990-03-09 1991-11-19 Tosoh Corp スルホンアミド誘導体、その製法及びそれを有効成分として含有する除草剤
JP2902834B2 (ja) 1991-10-09 1999-06-07 本田技研工業株式会社 自己伸縮型マウント
TW224462B (pl) 1992-02-24 1994-06-01 Squibb & Sons Inc
FR2690160A1 (fr) 1992-04-15 1993-10-22 Rhone Poulenc Rorer Sa Application de dérivés d'acide 2H-1,2,4-benzothiadiazine-1,1-dioxyde-3-carboxylique à la préparation de médicaments, les produits nouveaux, leur préparation et les médicaments les contenant.
NZ247440A (en) 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
EP0626174A3 (en) 1993-04-21 1996-01-03 Takeda Chemical Industries Ltd Method and composition for the prophylaxis and / or treatment of underactive organs.
JP3901229B2 (ja) 1994-05-13 2007-04-04 Ntn株式会社 耐熱・潤滑性樹脂組成物
EP1048657A1 (en) 1995-04-04 2000-11-02 Texas Biotechnology Corporation Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
EP0938477A4 (en) 1996-11-13 1999-12-29 Cephalon Inc BENZOTHIAZOLO AND RELATED HETEROCYCLIC GROUPS CONTAINING CYSTEIN AND SERINE PROTEASE INHIBITORS
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
ID25921A (id) 1997-04-28 2000-11-09 Texas Biotechnology Corp Sulfonamida-sulfonamida untuk pengobatan penyakit-penyakit yang dimediakan endotelin
NZ517828A (en) 1999-09-17 2003-10-31 Millennium Pharm Inc Inhibitors having activity against mammalian factor Xa
WO2001049289A1 (en) 1999-12-31 2001-07-12 Texas Biotechnology Corporation Pharmaceutical and veterinary uses of endothelin antagonists
CA2401778C (en) 2000-02-29 2010-12-21 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
GB0127344D0 (en) 2001-11-14 2002-01-02 Cancer Res Ventures Ltd Assay method
PL370447A1 (pl) 2001-11-22 2005-05-30 Biovitrum Ab Inhibitory dehydrogenazy 11-beta-hydroksysteroidów typu I
JP2003292485A (ja) 2002-04-01 2003-10-15 Yamanouchi Pharmaceut Co Ltd スルホンアミド誘導体
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
EP1631558A1 (en) 2003-05-21 2006-03-08 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i
WO2004113310A1 (en) 2003-06-25 2004-12-29 Biovitrum Ab Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing
AU2004259755A1 (en) 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Quinolinone derivatives as inhibitors of c-fms kinase
US7615563B2 (en) 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
TW200524888A (en) 2003-08-08 2005-08-01 Vertex Pharma Compositions useful as inhibitors of voltage-gated ion channels
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
RU2407736C2 (ru) 2004-10-12 2010-12-27 Декод Дженетикс Ехф Пери-замещенные арилсульфонамидные бициклические соединения, предназначенные для лечения окклюзионного заболевания артерий
DE602006012650D1 (de) 2005-04-26 2010-04-15 Hypnion Inc Benzisoxazolpiperidinverbindungen und verfahren zu deren anwendung
WO2006116615A1 (en) 2005-04-26 2006-11-02 Hypnion, Inc. Benzisoxazole piperazine compounds and methods of use thereof
US7745629B2 (en) 2005-05-16 2010-06-29 Vertex Pharmaceuticals Incorporated Bicyclic derivatives as modulators of ion channels
DE102005038947A1 (de) 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
CN101282969A (zh) 2005-10-06 2008-10-08 塞诺菲-安万特股份有限公司 双环芳基-磺酸[1,3,4]-噻二唑-2-基-酰胺、它们的制备方法以及它们作为药物的用途
JP2009510147A (ja) 2005-10-06 2009-03-12 サノフィ−アベンティス N−[1,3,4]−チアジアゾール−2−イル−ベンゼンスルホンアミド類、それらの製造方法及び医薬品としてのそれらの使用
DE102005055355A1 (de) 2005-11-21 2007-10-31 Merck Patent Gmbh 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate
WO2007075895A2 (en) 2005-12-21 2007-07-05 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
EP2054056A4 (en) 2006-08-16 2010-08-25 J David Gladstone Inst A Testa SMALL MOLECULAR INHIBITORS OF KYNURENINE-3-MONOOXYGENASE
WO2008064116A2 (en) 2006-11-16 2008-05-29 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
AU2007321921A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
WO2008089307A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
US8124610B2 (en) 2007-07-13 2012-02-28 Icagen Inc. Sodium channel inhibitors
AU2008319267A1 (en) 2007-11-01 2009-05-07 Sirtris Pharmaceuticals, Inc. Amide derivatives as sirtuin modulators
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
MX2010006647A (es) 2007-12-26 2010-08-17 Sanofi Aventis Piridil-n-[1,3,4]-tiadiazol-2-il-bencenosulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticos.
JP5774989B2 (ja) 2008-08-13 2015-09-09 スメド−ティーエイ/ティーディー・エルエルシー 整形外科用ねじ
WO2010046780A2 (en) 2008-10-22 2010-04-29 Institut Pasteur Korea Anti viral compounds
EP2421833B1 (en) 2009-04-21 2015-01-14 Nerviano Medical Sciences S.r.l. Resorcinol derivatives as hsp90 inhibitors
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
PT2471786E (pt) 2009-08-07 2016-03-04 Hoffmann La Roche Derivado de aminopirazol
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
CN101845043A (zh) 2010-01-15 2010-09-29 江苏省农药研究所股份有限公司 邻杂环甲酰苯胺类化合物及其合成方法和应用
CN101747325A (zh) 2010-01-15 2010-06-23 江苏省农药研究所股份有限公司 邻杂环甲酰苯胺类化合物及其合成方法和应用
WO2011085575A1 (zh) 2010-01-15 2011-07-21 江苏省农药研究所股份有限公司 邻杂环甲酰苯胺类化合物及其合成方法和应用
US20130109672A1 (en) 2010-04-29 2013-05-02 The United States Of America,As Represented By The Secretary, Department Of Health And Human Service Activators of human pyruvate kinase
TW201210597A (en) 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
JP2013532185A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
WO2012080729A2 (en) 2010-12-14 2012-06-21 Electrophoretics Limited CASEIN KINASE 1δ (CK1δ) INHIBITORS
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
PL220630B1 (pl) 2012-12-28 2015-11-30 Inst Immunologii I Terapii Doświadczalnej Pan Nowe sulfonamidowe pochodne izoksazolo[5,4-b]pirydyny o aktywności przeciwbakteryjnej, sposób ich wytwarzania oraz nowe zastosowanie 3-aminoizoksazolo[5,4-b]pirydyny
EP2970156B1 (en) 2013-03-15 2018-07-25 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
WO2015102929A1 (en) 2013-12-30 2015-07-09 Novartis Ag Tricyclic sulfonamide derivatives
EP3097101B1 (en) 2014-01-24 2020-12-23 Merck Sharp & Dohme Corp. Isoquinoline derivatives as mgat2 inhibitors
KR102458990B1 (ko) 2014-04-23 2022-10-25 미쓰비시 타나베 파마 코퍼레이션 신규한 바이시클릭 또는 트리시클릭 헤테로시클릭 화합물
JP5900759B2 (ja) 2014-09-25 2016-04-06 Toto株式会社 小便器
KR20170119705A (ko) 2015-02-24 2017-10-27 화이자 인코포레이티드 항암제로서 유용한 치환된 뉴클레오시드 유도체
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
WO2017002120A1 (en) 2015-07-02 2017-01-05 Yeda Research And Development Co. Ltd. Selective inhibitors of senescent cells and uses thereof
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
CN107098846B (zh) * 2016-02-26 2020-10-09 中国医学科学院药物研究所 N-酰基磺酰胺类FBPase抑制剂、其制备方法、药物组合物及用途
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
EP3548480A1 (en) * 2016-11-29 2019-10-09 Epizyme, Inc. Compounds containing a sulfonic group as kat inhibitors
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
FI3986890T3 (fi) 2019-06-18 2024-01-15 Pfizer Bentsisoksatsolisulfonamidijohdannaisia

Also Published As

Publication number Publication date
MA67365B1 (fr) 2025-10-31
PL4299135T3 (pl) 2025-11-12
ECSP21091615A (es) 2022-01-31
EP3986890B1 (en) 2023-11-15
EP3986890B9 (en) 2025-04-16
WO2020254946A1 (en) 2020-12-24
RS67276B1 (sr) 2025-10-31
LT4299135T (lt) 2025-09-10
HRP20251225T1 (hr) 2025-12-05
CR20210627A (es) 2022-02-08
US12371425B2 (en) 2025-07-29
FI3986890T3 (fi) 2024-01-15
RS64931B9 (sr) 2025-06-30
RS64931B1 (sr) 2023-12-29
JP2023175821A (ja) 2023-12-12
CA3143666A1 (en) 2020-12-24
DK3986890T3 (da) 2023-12-18
MD4299135T2 (ro) 2025-11-30
CL2021003372A1 (es) 2022-10-07
PH12021553107A1 (en) 2022-08-01
PE20220808A1 (es) 2022-05-20
EP4299135A3 (en) 2024-02-28
MY210207A (en) 2025-09-03
HUE064683T2 (hu) 2024-04-28
TWI787620B (zh) 2022-12-21
CN114364672A (zh) 2022-04-15
US20200399258A1 (en) 2020-12-24
PT4299135T (pt) 2025-10-09
LT3986890T (lt) 2023-12-11
CN114364672B (zh) 2024-09-06
HRP20231501T1 (hr) 2024-03-01
FI4299135T3 (fi) 2025-10-01
ES3043899T3 (en) 2025-11-26
IL288802A (en) 2022-02-01
DK4299135T3 (da) 2025-09-08
TW202115048A (zh) 2021-04-16
MD3986890T2 (ro) 2024-04-30
CA3143666C (en) 2024-06-11
SI3986890T1 (sl) 2024-03-29
MD3986890T3 (ro) 2025-07-31
ES2969616T3 (es) 2024-05-21
EP3986890A1 (en) 2022-04-27
AU2020296361A1 (en) 2022-01-06
CO2021017504A2 (es) 2022-01-17
IL288802B2 (en) 2025-08-01
MX2021016085A (es) 2022-04-20
IL288802B1 (en) 2025-04-01
UY38752A (es) 2021-01-29
UA129891C2 (uk) 2025-09-03
KR102823056B1 (ko) 2025-06-23
AU2023274178A1 (en) 2024-02-15
BR112021025528A2 (pt) 2022-04-19
US11492346B2 (en) 2022-11-08
KR20220024671A (ko) 2022-03-03
EP4299135A2 (en) 2024-01-03
EP4299135B1 (en) 2025-08-06
JP2022537285A (ja) 2022-08-25
US20230174522A1 (en) 2023-06-08
PT3986890T (pt) 2024-01-17
JP7352662B2 (ja) 2023-09-28

Similar Documents

Publication Publication Date Title
DK4299135T3 (da) Benzisoxazol-sulfonamid-derivater
IL283197A (en) Microbiocidal 2-acylamino-thiazole-4-carboxamide derivatives
PT3958977T (pt) Derivados de camptotecina
IL292161A (en) New methylquinazolinone derivatives
DK3761790T3 (da) Picolinamider som fungicider
DK3768674T3 (da) Aminopyrimidinderivater som ctps1-hæmmere
LT3830085T (lt) Deuterinti lanifibranoro dariniai
EP4013751C0 (en) 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES
EP3973221C0 (de) Stop & go-molch
DK3768669T3 (da) Piperazinazaspiroderivater
EP3773566A4 (en) OX2R COMPOUNDS
EP4077334C0 (en) FUROINDAZOLE DERIVATIVES
EP3919491C0 (en) AKT INHIBITOR
EP4021904C0 (en) ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES
AR120804A1 (es) Derivados de isoxazolina
IL283900A (en) Pharmaceutical combinations
DK3823970T3 (da) Yderligere substituerede triazoloquinoxalinderivater
DK3823971T3 (da) Substituerede triazol-quinoxalin-derivater
DK3796975T3 (da) Sulfonylaminobenzamidderivater
EP3957391C0 (en) AGITATOR
EP3962498A4 (en) Combination therapies
DK3894410T3 (da) Substituerede xanthinderivater
EP3898177C0 (en) MOLD CONFIGURATION
DK3738452T3 (da) Fordamper
DK3770162T3 (da) Dihydrochromenderivater